“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Starpharma
Starpharma is an Australian biotechnology company with two decades of experience in advancing dendrimer technologies from the lab to the patient.
Starpharma — 2 videos in collection
Starpharma held an investor webinar to present the preclinical data for its DEP HER2-targeted radiotherapy candidate, DEP HER2-Lutetium (DEP HER2-Lu). Starpharma’s chief executive officer, Cheryl Maley, and chief scientific and regulatory officer, Dr Jeremy Paull, discussed the DEP HER2-Lu data, the planned pathway towards a first-in-human Phase 1 study and the broader opportunity for Starpharma’s DEP platform in radiotheranostics. Key opinion leader Professor Tony Lahoutte, whose expertise includes nanobody-based imaging and radionuclide therapy, also shared his perspective.
Get access to the very latest content matched to your personal investment style.